You need certainty that your products will not pose mutagenic risks, that they meet international regulatory standards, and that your testing partner can deliver both speed and scientific rigour. At Eurofins BioPharma Product Testing (BPT) network of laboratories, genetic toxicology studies are designed to do exactly that. With a track record of complying with OECD, ICH, US-FDA, ISO, and EMEA guidelines, and with full GLP compliance, we help clients worldwide meet stringent regulatory expectations with confidence.

We offer comprehensive services of in vitro and in vivo genetic toxicology testing to assess the mutagenic potential of your product. While the majority of studies are performed in vitro, in some cases, in vivo genetic toxicology may be necessary. Our experienced scientific teams will advise you on the most appropriate testing strategy. Our familiarity with an array of different in vitro test systems enables us to provide contract testing services using the optimum assays to answer specific product safety and efficacy questions.

With the rise of new molecules synthesised in the pharmaceutical and chemical industries, there is growing demand for rapid assays that require minimal test material. To meet this need,  Eurofins BPT provides miniaturised screening tests, enabling the efficient screening of a high volume of substances. Alongside standard testing, we also offer customised testing with accelerated turnaround times, delivering fast, reliable, efficient results without compromising regulatory compliance.